Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Epithelial Ovarian Cancer: early-phase trial registry
18 of 42 indexed Epithelial Ovarian Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #347 of 28,707 conditions by registered trial count.
42 US clinical trials · 18 currently recruiting · #347 of 28,707 conditions by registered trial count
Epithelial Ovarian Cancer: 42 US clinical trials tracked, 18 recruiting.
Epithelial Ovarian Cancer is the subject of 42 registered US clinical trials on ClinicalTrials.gov, 18 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 34 in Phase 1-2 (earlier-stage). The most active sponsor is Imunon, running 3 of these trials.
Enrollment posture brief
Registry condition epithelial-ovarian-cancer
OPEN 18 | RECR 43% | LATE 5 | EARLY 34 | RANK #347 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Myelogenous Leukemia (AML) (43% recruiting · 7 trials)
Epithelial Ovarian Cancer lists 18 open slots (43% of 42 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Epithelial Ovarian Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Epithelial Ovarian Cancer is recruiting above its size-band peers.
18 of 42 indexed trials (42.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Epithelial Ovarian Cancer trials is spread across many organizations.
Imunon accounts for 3 of 42 trials (7.1%). 35 distinct sponsors appear on at least one study for this condition label.
-
Typical Epithelial Ovarian Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 42 trials that report a genuine target (sentinel values excluded). 23 of those (54.8%) plan for fewer than 100 participants.
-
Epithelial Ovarian Cancer research is mostly interventional.
42 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
42 total, page 1 of 1
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
AstraZeneca
NCT07218809
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Imunon
NCT06915025
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics
NCT05867251
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Bicara Therapeutics
NCT04429542
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
TORL Biotherapeutics
NCT06690775
A Study of ZN-c3 in Patients With Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals
NCT04516447
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
NCT06890338
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
858 Therapeutics
NCT06395519
A Study of Isoquercetin in People With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
NCT07303894
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Regeneron Pharmaceuticals
NCT06469281
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Blue Earth Diagnostics
NCT07432633
T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors
Alexander B Olawaiye, MD
NCT05200559
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics
NCT06756035
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
NCT04282044
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
Memorial Sloan Kettering Cancer Center
NCT05429970
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center
NCT06305299
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
Case Comprehensive Cancer Center
NCT06412510
Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer
Case Comprehensive Cancer Center
NCT06386887
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
Klus Pharma
NCT04152499
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
pharmaand
NCT03522246
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23andMe
NCT05199272
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries
NCT03872947
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
NCT04902872
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
Imunon
NCT03393884
TH1902 in Patients With Advanced Solid Tumors
Theratechnologies
NCT04706962
ITIL-306 in Advanced Solid Tumors
Instil Bio
NCT05397093
HOT: HIPEC in Ovarian Cancer as Initial Treatment
Mercy Medical Center
NCT02124421
Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
UNC Lineberger Comprehensive Cancer Center
NCT04670068
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
pharmaand
NCT01891344
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
AbbVie
NCT04209855
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Celgene
NCT01666444
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
NCT04925284
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
ImmunoGen
NCT04296890
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Yale University
NCT03093155
Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Stand
University of Utah
NCT01549925
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
Accelerated Community Oncology Research Network
NCT00407563
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
AA Secord
NCT02728830
Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT03332576
Neoadjuvant Therapy for Ovarian Cancer
Jason D. Wright
NCT01146795
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer
Imunon
NCT02480374
Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer
Morphotek
NCT01004380
Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
Prima BioMed
NCT01617629
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 24 |
| Phase 2 | 10 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Epithelial Ovarian Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Epithelial Ovarian Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Epithelial Ovarian Cancer page
42 registered trials, 18 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 18 Epithelial Ovarian Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Imunon sponsors the most Epithelial Ovarian Cancer trials on record, review their full trial history before evaluating a specific study. See Imunon's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Epithelial Ovarian Cancer condition card totals 42 registered trials; most-linked intervention Paclitaxel; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.